Theravance Biopharma(Delisted)
TBPH
17.03
0.00
0.00%
Theravance Biopharma(Delisted)
US · TBPH
#3330 by market cap
Listed 2015
17.03
0.00
0.00%
Live - 5344 symbols - heartbeat 455s ago
· 2026-10-07 19:54
- Market cap
- 884.18M
- P/E (TTM)i
- 16.38
- P/Bi
- 3.05
- EPSi
- 2.06
- Div yieldi
- 0.00%
- 52W posi
- 50%
Reader sentiment
Are you bullish or bearish on TBPH?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.47, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +66.92% YoY
Margins
- Operating margin
- -3.35%
- Net margin
- 98.54%
Key ratios & quality
- Altman Z-Scorei
- 1.47
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 60.37M | 73.41M | 71.86M | 55.31M | 51.35M | 57.42M | 64.38M | 107.46M |
| Gross profit | 59.66M | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 97.06M | 106.08M | 108.53M | 99.30M | 67.07M | 70.10M | 69.17M | 73.65M |
| Research & development | 201.35M | 219.25M | 260.95M | 193.66M | 63.39M | 40.62M | 37.64M | 37.41M |
| Operating profit | -238.75M | -251.92M | -297.63M | -237.64M | -79.12M | -53.29M | -42.44M | -3.60M |
| Pretax profit | -226.09M | -241.68M | -303.34M | -265.22M | -92.82M | -49.27M | -44.61M | 129.25M |
| Tax | -10.56M | -5.22M | -8.52M | -151.00K | 9.00K | 5.92M | 11.80M | 23.35M |
| Net profit | -215.52M | -236.46M | -278.02M | -199.43M | 872.13M | -55.19M | -56.42M | 105.90M |
| Basic EPS | -4 | -4 | -4 | -3 | 12 | -1 | -1 | 2 |
| Diluted EPS | -3.99 | -4.25 | -4.46 | -2.87 | 11.85 | -1.00 | -1.15 | 2.06 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 15.39M | 26.20M | 19.99M | 45.89M | 17.70M | 20.73M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 18.37M | 18.43M | 18.33M | 18.52M | 17.72M | 14.18M |
| Research & development | 11.45M | 10.49M | 8.11M | 7.36M | 5.83M | 4.71M |
| Operating profit | -14.43M | -2.73M | -6.46M | 20.01M | -5.85M | 1.84M |
| Pretax profit | -14.14M | 73.21M | -2.89M | 73.07M | -6.47M | -4.79M |
| Tax | -559.00K | 18.37M | -6.50M | 12.04M | -1.54M | 1.11M |
| Net profit | -13.58M | 54.84M | 3.62M | 61.02M | -4.93M | -5.90M |
| Basic EPS | 0 | 1 | 0 | 1 | 0 | 0 |
| Diluted EPS | -0.27 | 1.08 | 0.07 | 1.15 | -0.10 | -0.11 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 532.82M | 338.49M | 393.34M | 249.87M | 353.46M | 133.54M | 161.07M | 418.46M |
| Cash & ST investments | 505.28M | 280.83M | 292.94M | 173.47M | 327.48M | 102.43M | 88.35M | 315.36M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 560.24M | 408.83M | 469.06M | 374.82M | 607.40M | 382.00M | 354.16M | 485.57M |
| Total current liabilities | 98.55M | 111.70M | 123.57M | 58.59M | 28.72M | 24.77M | 32.09M | 38.30M |
| Short-term debt | -- | 17.61M | 29.20M | 17.44M | 6.75M | 3.92M | 10.71M | 10.95M |
| Long-term debt | 454.35M | 445.19M | 599.84M | 599.39M | -- | -- | -- | -- |
| Total liabilities | 611,824,000.00 | 632,666,000.00 | 772,808,000.00 | 713,392,000.00 | 165,600,000.00 | 169,004,000.00 | 178,616,000.00 | 188,847,000.00 |
| Total equity | -51.59M | -223.84M | -303.75M | -338.57M | 441.80M | 213.00M | 175.55M | 296.72M |
| Retained earnings | -1.01B | -1.25B | -1.53B | -1.73B | -853.91M | -909.10M | -965.52M | -859.63M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 150.26M | 366.29M | 354.70M | 418.46M | 417.63M | 416.66M |
| Cash & ST investments | 130.86M | 338.80M | 329.68M | 315.36M | 394.67M | 387.66M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 343.58M | 426.04M | 415.46M | 485.57M | 472.31M | 469.77M |
| Total current liabilities | 31.50M | 54.63M | 37.41M | 38.30M | 31.78M | 30.77M |
| Short-term debt | 10.81M | 10.90M | 10.91M | 10.95M | 10.75M | 10.80M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 177,599,000.00 | 201,187,000.00 | 182,779,000.00 | 188,847,000.00 | 181,719,000.00 | 180,065,000.00 |
| Total equity | 165.98M | 224.85M | 232.68M | 296.72M | 290.59M | 289.71M |
| Retained earnings | -979.10M | -924.27M | -920.65M | -859.63M | -864.56M | -870.46M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -112.87M | -238.20M | -250.40M | -207.86M | -186.99M | -27.00M | -11.54M | 238.54M |
| Depreciation & amortization | 3.17M | 6.21M | 6.97M | 8.60M | 7.02M | 4.26M | 3.62M | 2.81M |
| Free cash flow | -120.11M | -241.37M | -257.02M | -211.26M | -187.56M | -29.49M | -11.87M | 238.50M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -9.81M | -3.17M | 130.17M | 99.12M | -132.28M | -199.55M | -3.01M | -4.01M |
| Ending cash balance | 378.85M | 58.90M | 82.30M | 90.80M | 299.01M | 40.38M | 38.63M | 168.64M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 43.04M | 208.07M | -6.51M | -6.06M | 73.28M | -6.97M |
| Depreciation & amortization | 1.05M | 927.00K | 636.00K | 196.00K | 835.00K | 506.00K |
| Free cash flow | 43.04M | 208.04M | -6.51M | -6.07M | 73.28M | -6.97M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -854.00K | -503.00K | -678.00K | -1.98M | -5.82M | -2.10M |
| Ending cash balance | 111.45M | 282.76M | 175.61M | 168.64M | 288.94M | 220.60M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -677.87 | -- | -- | -- | 1,689.74 | -16.86 | -29.04 | 44.85 |
| ROA %i | -43.03 | -48.80 | -63.34 | -47.26 | 177.58 | -11.16 | -15.33 | 25.22 |
| ROIC %i | -58.50 | -- | -- | -- | 211.06 | -15.93 | -23.86 | 35.26 |
| 5-year avg ROE %i | -221.40 | -- | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -357.14 | -285.80 | -336.71 | -276.05 | -168.36 | -81.71 | -65.34 | 122.56 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | 221.93 |
| Current ratioi | 5.41 | 3.03 | 3.18 | 4.26 | 12.31 | 5.39 | 5.02 | 10.93 |
| Quick ratioi | 5.29 | 2.97 | 2.93 | 3.94 | 11.99 | 4.84 | 4.89 | 10.73 |
| Debt / assetsi | 81.10 | 124.88 | 144.17 | 178.62 | 8.59 | 12.87 | 14.07 | 8.79 |
| LT debt / equityi | -- | -- | -- | -- | 10.28 | 21.24 | 22.28 | 10.70 |
| Interest coveragei | -20.57 | -6.59 | -5.43 | -3.26 | -13.57 | -19.97 | -16.52 | 53.52 |
| Revenue CAGR (3Y) %i | 12.74 | 14.70 | 67.15 | -2.88 | -11.23 | -7.20 | 5.19 | 27.91 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -50.48 |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -31.46 | 6.23 | 14.03 | 44.85 | 50.17 | 20.91 |
| ROA %i | -16.32 | 3.31 | 7.61 | 25.22 | 28.08 | 12.01 |
| ROIC %i | -25.57 | 4.47 | 10.35 | 35.26 | 38.81 | 13.95 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -70.16 | 55.25 | 61.95 | 122.56 | 126.38 | 57.59 |
| FCF / sales %i | 49.47 | 317.05 | 303.11 | 221.93 | 244.81 | 51.51 |
| Current ratioi | 4.77 | 6.70 | 9.48 | 10.93 | 13.14 | 13.54 |
| Quick ratioi | 4.64 | 6.60 | 9.30 | 10.73 | 12.91 | 13.26 |
| Debt / assetsi | 14.02 | 10.90 | 10.73 | 8.79 | 8.58 | 8.21 |
| LT debt / equityi | 22.50 | 15.82 | 14.48 | 10.70 | 10.24 | 9.59 |
| Interest coveragei | -17.89 | 16.54 | 19.73 | 53.52 | 76.31 | 52.01 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Development and commercialization of human therapeutics100.00%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.